The 2018 ASCO Annual Meeting featured the results of multiple large phase III trials aimed at establishing whether the use of PD-1/PD-L1 checkpoint inhibitors can enhance outcomes in metastatic non–small cell lung cancer (NSCLC).
Amidst the flood of immunotherapy trials being conducted in non–small cell lung cancer (NSCLC), interim data from two pivotal phase III trials of atezolizumab are beginning to inform if and how the anti–PD-L1 inhibitor may be used in the first-line setting.
Adding bevacizumab to the tyrosine kinase inhibitor (TKI) erlotinib significantly extended progression free-survival (PFS) in patients with late-stage or recurrent chemotherapy-naive EGFR-mutated non–small cell lung cancer (NSCLC) with good tolerability.
Dacomitinib is a second-generation EGFR tyrosine kinase inhibitor (TKI). This agent was compared with gefitinib in the phase III open-label ARCHER1050 trial in patients with advanced non–small cell lung cancer (NSCLC) with EGFR-activating mutations.
Combining pembrolizumab with conventional chemotherapy in the first-line setting significantly prolongs median overall survival (OS) in patients with metastatic squamous non–small cell lung cancer (NSCLC)
Both nivolumab alone and in combination with ipilimumab resulted in a promising disease control rate in patients with relapsing malignant pleural mesothelioma (MPM), according to the results of Abstract LBA8507.
The EGFR tyrosine-kinase inhibitor gefitinib appears to offer a disease-free survival benefit over vinorelbine/cisplatin as adjuvant therapy in patients with non–small cell lung cancer with EGFR-activating mutation.
Researchers overseeing the trial at Roswell Park discuss the effectiveness of CIMAvax-EGF in NSCLC, the results of completed clinical trials in Cuba, and the long-term plans for additional testing of the vaccine.
Smoking not only causes many forms of cancer, but continued smoking by people with cancer and cancer survivors causes adverse health outcomes, including increased overall mortality, cancer-specific mortality, and risk for second primary cancer and is associated with increased treatment toxicity.